Perathiepin

{{Short description|Chemical compound}}

{{Drugbox

| IUPAC_name = 1-(10,11-dihydrodibenzo[b,f]thiepin-10-yl)-4-methylpiperazine

| image = Perathiepin.svg

| width = 200px

| CAS_number_Ref = {{cascite|correct|CAS}}

| CAS_number = 1526-83-6

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = YR8C4WXJ4T

| ATC_prefix = None

| ATC_suffix =

| PubChem = 107593

| ChemSpiderID = 96790

| C = 19 | H = 22 | N = 2 | S = 1

| SMILES = S2c1ccccc1CC(c3c2cccc3)N4CCN(C)CC4

| StdInChI = 1S/C19H22N2S/c1-20-10-12-21(13-11-20)17-14-15-6-2-4-8-18(15)22-19-9-5-3-7-16(17)19/h2-9,17H,10-14H2,1H3

| StdInChIKey = MYFNXITXHNLSJY-UHFFFAOYSA-N

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| pregnancy_category =

| legal_status =

| routes_of_administration =

}}

Perathiepin is a neuroleptic drug of the tricyclic family which was developed in the 1960s but was never marketed. In animal studies it was found to possess central depressant, antihistamine, antiserotonergic, and analgesic effects.{{cite book | vauthors = Rosowsky A | title = Chemistry of heterocyclic compounds | url = https://books.google.com/books?id=LpUNkInB2ncC&pg=PA796 | access-date = 26 November 2011 | year = 1972 | publisher = John Wiley & Sons | isbn = 978-0-471-38210-2 | pages = 796–797}}{{cite book | vauthors = Harbert CA, Welch MW | chapter = Antipsychotic and Antianxiety Agents | veditors = Henzelmann RV, Gordon M | title = Annual Reports in Medicinal Chemistry | chapter-url = https://books.google.com/books?id=rZBH1_7Tx6UC&pg=PA2 | access-date = 26 November 2011 | date = 1 September 1974 | volume = 9 | publisher = Academic Press | isbn = 978-0-12-040509-1 | pages = 1–10 (2) | doi = 10.1016/S0065-7743(08)61422-0 }}